Celgene (NASDAQ: CELG) received a number of price target changes and ratings updates during the last week:

  • Celgene had its “buy” rating reaffirmed by analysts at Lazard Capital. They now have a $85.00 price target on the stock.
  • Celgene had its “outperform” rating reaffirmed by analysts at Cowen.
  • Celgene had its “neutral” rating reaffirmed by analysts at Credit Suisse. They now have a $75.00 price target on the stock.
  • Celgene had its price target raised by analysts at Bank of America from $76.00 to $88.00. They now have a “buy” rating on the stock.
  • Celgene had its price target raised by analysts at Jefferies Group to $91.00. They now have a “buy” rating on the stock.
  • Celgene had its “sector perform” rating reaffirmed by analysts at RBC Capital. They now have a $75.00 price target on the stock.

Shares of Celgene opened at 78.99 on Thursday. Celgene has a 52 week low of $58.53 and a 52 week high of $80.42. The company has a market cap of $34.078 billion and a P/E ratio of 22.80.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.